Last updated on March 2017

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy


Other Details:

In this study, 2 out of 3 people will get niraparib and 1 out of 3 people will get placebo. Participants must have completed a front-line platinum based chemotherapy regimen with a Complete Response or Partial Response as determined by their doctor.

Those with Stage III disease must have cancer that remains after surgery (if surgery was an option). Participants must have a normal or more than 90% decrease in their CA-125 after front-line platinum chemotherapy.



Find a site near you

Start Over
Sorry. There are no research sites conducting this study in the radius provided. ( View all Sites )
If you would like to be informed of other studies that may be of interest to you, you may sign up for CenterWatch.com's Patient Notification Service.